MX337778B - Anticuerpos contra il-22 humana y usos para los mismos. - Google Patents
Anticuerpos contra il-22 humana y usos para los mismos.Info
- Publication number
- MX337778B MX337778B MX2013009826A MX2013009826A MX337778B MX 337778 B MX337778 B MX 337778B MX 2013009826 A MX2013009826 A MX 2013009826A MX 2013009826 A MX2013009826 A MX 2013009826A MX 337778 B MX337778 B MX 337778B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- antibodies against
- against human
- antibodies
- uses therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un anticuerpo o fragmento del mismo que une a antígeno, qua se une específicamente a IL-22, caracterizado porque comprende: (a) un dominio VH con SEQ ID NO: 134, SEQ ID NO: 135 y SEQ ID NO: 136 y un dominio VL con SEQ ID NO: 137, SEQ ID NO: 138 y SEQ ID NO: 139; (b) un dominio VH con SEQ ID NO: 152, SEQ ID NO: 153 y SEQ ID NO: 154 y un dominio VL con SEQ ID NO: 155, SEQ ID NO: 156 y SEQ ID NO: 157; (c) un dominio VH con SEQ ID NO: 170, SEQ ID NO: 171 y SEQ ID NO: 172 y un dominio VL con SEQ ID NO: 173, SEQ ID NO: 174 y SEQ ID NO: 175; (d) un dominio VH con SEQ ID NO; 188, SEQ ID NO: 189 y SEQ ID NO: 190 y un dominio VL con SEQ ID NO: 191, SEQ ID NO: 192 y SEQ ID NO: 193; (e) un dominio VH con SEQ ID NO: 206, SEQ ID NO: 207 y SEQ ID NO: 208 y un dominio VL con SEQ ID N0: 209, SEQ ID NO: 210 y SEQ ID NO: 211; (e) un dominio VH con SEQ ID NO: 224, SEQ ID NO: 225 y SEQ ID NO: 226 y un dominio VL con SEQ ID NO: 227, SEQ ID NO: 228 y SEQ ID NO: 229; (g) un dominio VH con SEQ ID NO: 242, SEQ ID NO: 243 y SEQ ID NO: 244 y un dominio VL con SEQ ID NO: 245, SEQ ID NO: 246 y SEQ ID NO: 247; (h) un dominio VH con SEQ ID NO: 260, SEQ ID NO: 261 y SEQ ID NO: 262 y un dominio VL con SEQ ID NO: 263, SEQ ID NO: 264 y SEQ ID NO: 265; (i) un dominio VH con SEQ ID NO: 278, SEQ ID NO: 279 y SEQ ID NO: 280 y un dominio VL con SEQ ID NO: 281, SEQ ID NO: 282 y SEQ ID NO: 283; (j) un dominio VH con SEQ ID NO: 494, SEQ ID NO: 495 y SEQ ID NO: 496 y un dominio VL con SEQ ID NO: 497, SEQ ID NO: 498 y SEQ ID NO: 499; (k) un dominio VH con SEQ ID NO: 530, SEQ ID NO: 531 y SEQ ID NO: 532 y un dominio VL con SEQ ID NO: 533, SEQ ID NO: 534 y SEQ ID NO: 535; (l) un dominio VH con SEQ ID NO: 548, SEQ ID NO: 549 y SEQ ID NO: 550 y un dominio VL con SEQ ID NO: 551, SEQ ID NO: 552 y SEQ ID NO: 553; (m) un dominio VH con SEQ ID NO: 566, SEQ ID NO: S67 y SEQ ID NO: 568 y un dominio VL con SEQ ID NO: 569, SEQ ID NO: 570 y SEQ ID NO: 571; (n) un dominio VH con SEQ ID NO: 584, SEQ ID N0: S85 y SEQ ID NO: 586 y un dominio VL con SEQ ID NO: 587, SEQ ID NO: 588 y SEQ ID NO: 589; (o) un dominio VH con SEQ ID NO: 602, SEQ ID NO: 603 y SEQ ID NO: 604 y un dominio VL con SEQ ID NO: 605, SEQ ID NO: 606 y SEQ ID NO: 607; o (p) un dominio VH con SEQ ID NO: 620, SEQ ID N0: 621 y SEQ ID NO: 622 y un dominio VL con SEQ ID NO: 623, SEQ ID NO: 624 y SEQ ID NO: 625; y en donde (i) la constante de asociación del anticuerpo para IL-22 humano es por lo menos 1010 M-1, (ii) el anticuerpo bloquea la proliferación mediada por IL-22 de células BaF3 con un CI50 de 150 pM o menor y en donde las células BaF3 comprenden un receptor IL-22 humano; o (iii) el anticuerpo bloquea la secreción de GROa mediada por IL-22 de células HT29 con un C150 de 150 pM o menor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77459606P | 2006-02-21 | 2006-02-21 | |
| PCT/US2007/004430 WO2007098170A1 (en) | 2006-02-21 | 2007-02-21 | Antibodies against human il-22 and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX337778B true MX337778B (es) | 2016-03-18 |
Family
ID=38236225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009826A MX337778B (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
| MX2008010708A MX2008010708A (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008010708A MX2008010708A (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7901684B2 (es) |
| EP (3) | EP3020729B1 (es) |
| JP (1) | JP5150516B2 (es) |
| KR (2) | KR101616712B1 (es) |
| CN (1) | CN101426816B (es) |
| AR (1) | AR059604A1 (es) |
| AT (1) | ATE538137T1 (es) |
| AU (1) | AU2007217751B2 (es) |
| BR (1) | BRPI0708101B8 (es) |
| CA (1) | CA2643226C (es) |
| CR (1) | CR10237A (es) |
| DK (2) | DK3020729T3 (es) |
| EC (1) | ECSP088751A (es) |
| ES (2) | ES2377463T3 (es) |
| HK (1) | HK1120813A1 (es) |
| HN (1) | HN2008001292A (es) |
| HU (1) | HUE044595T2 (es) |
| IL (1) | IL193605A (es) |
| MX (2) | MX337778B (es) |
| MY (1) | MY146664A (es) |
| NO (1) | NO20083715L (es) |
| NZ (1) | NZ570878A (es) |
| PE (1) | PE20080111A1 (es) |
| PL (2) | PL3020729T3 (es) |
| PT (2) | PT1991584E (es) |
| RU (1) | RU2467016C2 (es) |
| SA (1) | SA07280062B1 (es) |
| SG (1) | SG172628A1 (es) |
| SI (2) | SI3020729T1 (es) |
| TW (1) | TWI417301B (es) |
| WO (1) | WO2007098170A1 (es) |
| ZA (1) | ZA200807278B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2530857T3 (es) * | 1999-04-28 | 2015-03-06 | Genetics Inst Llc | Proteínas GIL-19/AE289 humanas y polinucleótidos que codifican las mismas |
| CN105859886A (zh) | 2005-12-02 | 2016-08-17 | 健泰科生物技术公司 | 牵涉与il-22和il-22r结合的抗体的组合物和方法 |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| MX2011002153A (es) * | 2008-08-28 | 2011-03-29 | Wyeth Llc | Usos de citocinas de las familias de interleucina-22, interleucina-17 e interleucina-1 en enfermedades autoinmunitarias. |
| US9506919B2 (en) | 2009-04-13 | 2016-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for detecting the presence of an analyte in a sample |
| EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
| US10101299B2 (en) | 2010-03-12 | 2018-10-16 | The Board Of Trustees Of The Leland Standford Junior University | Magnetic sensor based quantitative binding kinetics analysis |
| EP2566890A4 (en) * | 2010-05-03 | 2013-11-20 | Abbvie Inc | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| WO2014015133A1 (en) * | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
| DK2890711T3 (en) * | 2012-08-31 | 2017-02-27 | Argen-X Nv | Process for Preparation of Inter-species, Intra-Target Cross-Reactivity Antibody Molecules |
| SG11201507429TA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| CN105139918B (zh) * | 2015-06-26 | 2017-04-12 | 哈尔滨工业大学 | 一种柔板印刷用低银高性能导电浆料及其制备方法 |
| CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
| WO2018039107A1 (en) * | 2016-08-22 | 2018-03-01 | Medimmune, Llc | Binding molecules specific for notch4 and uses thereof |
| CN110402393A (zh) * | 2016-11-24 | 2019-11-01 | 休伯特保健公司 | 疾病诊断的组合物 |
| BR112019008727A2 (pt) | 2016-11-28 | 2019-07-16 | Chugai Pharmaceutical Co Ltd | domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte |
| BR112020010450A2 (pt) | 2017-11-28 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora |
| KR102536314B1 (ko) * | 2018-05-23 | 2023-05-25 | 주식회사 휴벳바이오 | 질환의 진단용 조성물 |
| SG11202012014UA (en) | 2018-06-05 | 2021-01-28 | Bioatla Inc | Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| JP7323608B2 (ja) * | 2018-10-11 | 2023-08-08 | アリヴィオ セラピューティクス， インコーポレイテッド | スマート放出のための非注射用ヒドロゲル製剤 |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
| JP2023551983A (ja) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | インターロイキン－２２に対する抗体 |
| MX2023006650A (es) | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos. |
| EP4301777A1 (en) | 2021-03-02 | 2024-01-10 | Dana-Farber Cancer Institute, Inc. | Methods of treating red blood cell disorders |
| WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5833976A (en) | 1991-08-06 | 1998-11-10 | Schering Corporation | Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US5536637A (en) | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5674487A (en) | 1994-09-28 | 1997-10-07 | Univ Jefferson | Method for treating autoimmune diseases |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
| AU2576697A (en) | 1996-04-19 | 1997-11-12 | Chugai Seiyaku Kabushiki Kaisha | Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient |
| JP2000515002A (ja) | 1996-06-27 | 2000-11-14 | フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
| US6492507B1 (en) | 1996-10-23 | 2002-12-10 | Incyte Genomics, Inc. | Polynucleotides encoding human eosinophil-derived basic protein |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| WO2002016611A2 (en) | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US20030032057A1 (en) | 1997-08-26 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6350892B1 (en) | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| ATE553129T1 (de) | 1998-01-23 | 2012-04-15 | Hoffmann La Roche | Antikörper gegen humanes il-12 |
| CA2329274A1 (en) | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
| US20010023070A1 (en) | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
| US7081528B2 (en) | 1998-10-26 | 2006-07-25 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding T cell derived inducible factors |
| BR9914777A (pt) | 1998-10-26 | 2001-07-03 | Ludwig Inst Cancer Res | Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| CZ303725B6 (cs) | 1999-03-25 | 2013-04-03 | Abbott Gmbh & Co. Kg | Lidské protilátky, které se vází na lidský IL-12 a zpusoby jejich produkce |
| US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| WO2000070049A2 (en) | 1999-05-19 | 2000-11-23 | Incyte Genomics, Inc. | Extracellular signaling molecules |
| AU5047600A (en) | 1999-05-27 | 2000-12-18 | Schering Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| JP2003529324A (ja) | 1999-06-15 | 2003-10-07 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| DE60043895D1 (de) | 1999-12-03 | 2010-04-08 | Zymogenetics Inc | Menschliches zytokinrezeptor |
| US20030170823A1 (en) | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| DE60043944D1 (de) | 1999-12-23 | 2010-04-15 | Zymogenetics Inc | Zytokin zcyt018 |
| MXPA02007291A (es) | 2000-01-27 | 2002-11-29 | American Cyanamid Co | Metodo para preparar derivados de acido alfa-sulfonil hidroxamico. |
| TWI335336B (es) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| US20030012788A1 (en) | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| WO2002010393A2 (en) | 2000-07-27 | 2002-02-07 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| US7094570B2 (en) | 2003-03-11 | 2006-08-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| BR0207528A (pt) | 2001-02-23 | 2006-01-17 | Inst Genetics Llc | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20020187512A1 (en) | 2001-09-10 | 2002-12-12 | Nagem Ronaldo Alves Pinto | Crystal structure of human interleukin-22 |
| WO2003083062A2 (en) | 2002-03-22 | 2003-10-09 | Zymogenetics, Inc. | Anti-il-tif antibodies and methods of using in inflammation |
| EP1534752B1 (en) * | 2002-05-01 | 2011-08-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| KR20060022289A (ko) * | 2003-06-23 | 2006-03-09 | 제네틱스 인스티튜트, 엘엘씨 | 인터류킨-22 에 대한 항체 및 그의 용도 |
| CA2612746A1 (en) | 2005-07-04 | 2007-01-11 | Samsung Electronics Co., Ltd. | Position measuring system and method using wireless broadband (wibro) signal |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
-
2007
- 2007-02-16 TW TW096106166A patent/TWI417301B/zh active
- 2007-02-20 US US11/708,061 patent/US7901684B2/en active Active
- 2007-02-21 AU AU2007217751A patent/AU2007217751B2/en active Active
- 2007-02-21 MX MX2013009826A patent/MX337778B/es unknown
- 2007-02-21 HU HUE15184078 patent/HUE044595T2/hu unknown
- 2007-02-21 SG SG2011037538A patent/SG172628A1/en unknown
- 2007-02-21 ES ES07751204T patent/ES2377463T3/es active Active
- 2007-02-21 SA SA07280062A patent/SA07280062B1/ar unknown
- 2007-02-21 KR KR1020147021161A patent/KR101616712B1/ko active IP Right Grant
- 2007-02-21 PT PT07751204T patent/PT1991584E/pt unknown
- 2007-02-21 DK DK15184078.2T patent/DK3020729T3/da active
- 2007-02-21 SI SI200732116T patent/SI3020729T1/sl unknown
- 2007-02-21 PL PL15184078T patent/PL3020729T3/pl unknown
- 2007-02-21 MY MYPI20083190A patent/MY146664A/en unknown
- 2007-02-21 DK DK07751204.4T patent/DK1991584T3/da active
- 2007-02-21 PT PT15184078T patent/PT3020729T/pt unknown
- 2007-02-21 AT AT07751204T patent/ATE538137T1/de active
- 2007-02-21 WO PCT/US2007/004430 patent/WO2007098170A1/en active Application Filing
- 2007-02-21 EP EP15184078.2A patent/EP3020729B1/en active Active
- 2007-02-21 ES ES15184078T patent/ES2738731T3/es active Active
- 2007-02-21 MX MX2008010708A patent/MX2008010708A/es active IP Right Grant
- 2007-02-21 EP EP07751204A patent/EP1991584B1/en active Active
- 2007-02-21 PE PE2007000189A patent/PE20080111A1/es active IP Right Grant
- 2007-02-21 RU RU2008134137/10A patent/RU2467016C2/ru active
- 2007-02-21 BR BRPI0708101A patent/BRPI0708101B8/pt active IP Right Grant
- 2007-02-21 PL PL07751204T patent/PL1991584T3/pl unknown
- 2007-02-21 CA CA2643226A patent/CA2643226C/en active Active
- 2007-02-21 KR KR1020087023020A patent/KR20080113214A/ko active Search and Examination
- 2007-02-21 EP EP11188458.1A patent/EP2431392B1/en not_active Withdrawn - After Issue
- 2007-02-21 SI SI200730795T patent/SI1991584T1/sl unknown
- 2007-02-21 JP JP2008556389A patent/JP5150516B2/ja active Active
- 2007-02-21 CN CN2007800140240A patent/CN101426816B/zh active Active
- 2007-02-21 NZ NZ570878A patent/NZ570878A/en unknown
- 2007-02-22 AR ARP070100742A patent/AR059604A1/es active IP Right Grant
-
2008
- 2008-08-20 HN HN2008001292A patent/HN2008001292A/es unknown
- 2008-08-21 IL IL193605A patent/IL193605A/en active IP Right Grant
- 2008-08-22 CR CR10237A patent/CR10237A/es unknown
- 2008-08-22 ZA ZA200807278A patent/ZA200807278B/xx unknown
- 2008-08-28 NO NO20083715A patent/NO20083715L/no not_active Application Discontinuation
- 2008-09-19 EC EC2008008751A patent/ECSP088751A/es unknown
-
2009
- 2009-01-06 HK HK09100101.7A patent/HK1120813A1/xx unknown
- 2009-05-29 US US12/474,644 patent/US8187603B2/en active Active
-
2010
- 2010-01-29 US US12/696,434 patent/US8182817B2/en active Active
-
2012
- 2012-05-22 US US13/477,717 patent/US8470993B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY146664A (en) | Antibodies against human il-22 and uses therefor | |
| TW200744634A (en) | Methods of using antibodies against human IL-22 | |
| EP1603949B8 (en) | Antibodies against human il-21 receptor and uses therefor | |
| ATE514713T1 (de) | Antikörper gegen pd-1 und ihre verwendung | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| PH12014502527A1 (en) | St2 antigen binding proteins | |
| MY160590A (en) | Cd127 binding proteins | |
| MY162511A (en) | Engineered anti-tslp antibody | |
| MY181422A (en) | Human antibodies to fel d1 and methods of use thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
| MY149448A (en) | Interleukin-21 receptor binding proteins | |
| AR072136A1 (es) | Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21 | |
| TH97938A (th) | แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น | |
| TH97938B (th) | แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น | |
| ECSP056015A (es) | Anticuerpos contra el receptor de il-21 humano y usos de los mismos |